Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of subcutaneous lunsekimig (SAR443765) in adults with high-risk asthma not eligible for biologic treatment
2024-513959-33-00Phase 2Authorised
- Sponsor
- Sanofi
- Start
- May 2025
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 23
01
Overview
Phase 2, randomised, double-blind trial in asthma comparing lunsekimig with placebo (2 arms). Primary endpoint: Annualized rate of asthma exacerbation events. Planned start May 2025; status: authorised.
02
Drugs
lunsekimig
03
Conditions
asthma
Beyond the preview
Go deeper on 2024-513959-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513959-33-00.